Order Article Reprints

Branche A, Mulligan MJ, Maniar A, Puente O, Oladipupo I, Crowther G, Zareba AM, Yi Z, Scully I, Gomme E, et al. A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines. 2025; 13(4):383. https://doi.org/10.3390/vaccines13040383

Branche, Angela, Mark J. Mulligan, Alok Maniar, Orlando Puente, Islamiat Oladipupo, Graham Crowther, Agnieszka M. Zareba, Zhuobiao Yi, Ingrid Scully, Emily Gomme, and et al. 2025. "A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults" Vaccines 13, no. 4: 383. https://doi.org/10.3390/vaccines13040383

Branche, A., Mulligan, M. J., Maniar, A., Puente, O., Oladipupo, I., Crowther, G., Zareba, A. M., Yi, Z., Scully, I., Gomme, E., Koury, K., Kitchin, N., Allen, P. S., Anderson, A. S., Gurtman, A., & Lindert, K. (2025). A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines, 13(4), 383. https://doi.org/10.3390/vaccines13040383